Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. - Wikidata - awgldk - TriplyDB

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

http://www.wikidata.org/entity/Q37164590

about

Cancer Precision Medicine in China.Metastatic lung cancer in the age of targeted therapy: improving long-term survival.Bronchoalveolar Lavage Proteomics in Patients with Suspected Lung Cancer Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma.Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions.Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer.Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report.Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.STIM1 silencing inhibits the migration and invasion of A549 cells.Update in Lung Cancer 2015.Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC).Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report.Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report.Preface on "Emerging treatment options for brain metastases from non-small cell lung cancer".Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation.Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma.Circulating DNA in EGFR-mutated lung cancer.Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice.Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.CBX3/heterochromatin protein 1 gamma is significantly upregulated in patients with non-small cell lung cancer.Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors.miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis.Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance.Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option.EGFR targeted therapy for lung cancer: are we almost there?Identification of ceRNA network based on a RNA-seq shows prognostic lncRNA biomarkers in human lung adenocarcinoma Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

P2860

Q37390525-A87F085C-F84E-4764-AEF4-B1B1A1838A41 Q37584403-74169B20-2388-4F5C-954B-D7BCEF72942E Q37627629-589B5229-02AF-4EDB-89DC-B9F79CE956AF Q37678950-CF0B33F9-2EE1-426A-9EB4-8BECA345F529 Q37702099-B2AEC154-A416-4B18-ADB4-78D554DFE440 Q37702787-05849C5B-3E5B-4B02-BF1F-066FCFA3F4E6 Q37731945-EC1F22E1-2E0E-4EA3-B1EC-3DDD5F129155 Q39179464-48F47B3B-0E82-444E-8A8E-93034A01EFAB Q40120592-FC933AA3-D9DA-439E-910B-619DF0E7F0CB Q41115829-BD3F8D19-DD98-4741-B431-D33E17028C09 Q41182555-6CD7ACBD-D865-4443-B6EF-E14FEC236209 Q41356054-06C9DEAE-1615-4AB5-91F5-7D6C2819A1A3 Q41544052-7667E1F9-4412-4978-8878-D096E63DC870 Q42330752-F9269F87-B720-47AE-A9B7-A916BC2052D8 Q42668078-07786386-021C-41B7-9F2E-A319D9DD8BB7 Q46299389-1DE596E2-A639-4D36-9BA9-50A7D09ADA24 Q46917029-325893E1-0EFE-4EFB-9ED1-4EE352076F46 Q47147399-79284181-2B49-439B-B831-E63BCD53E456 Q47220604-3BFC46B0-5969-4C29-A7F4-74D2C7E53C37 Q47307357-625ADBC1-CFD5-4A1A-A920-3F8653CF9884 Q47417530-F6801B80-0669-468C-85EE-3515B28F2CC2 Q47855146-5C541128-074A-48CC-AB40-270AA1418623 Q49888038-1608DECB-409E-4EA0-8F7B-55628D4D75A3 Q49980448-A3A96620-D2A4-4643-AEA9-1F271B963C27 Q52597593-737B32AC-A6CF-43E1-A5A7-A7899FE22DB8 Q52655439-50256BE8-3375-4F24-BE08-5D53B7B38328 Q54115504-CE4ED015-5082-4598-883A-27915FA54DF0 Q55383949-3DDF9582-5A2D-453E-B689-01CD7C3CD4F4 Q55405362-9878542D-473A-4E76-BCF2-FDBE9317E02F Q57788791-F8139027-D82F-485A-8310-96D728C253D6 Q58562294-B35F4241-1DDF-4661-9A6A-5CE02BF8495E Q58562303-9D6CE57D-C490-4976-B9B7-06119A69D579

P2860

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

http://www.wikidata.org/entity/Q37164590

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 December 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

@en

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

@nl

type

label

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

@en

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

@nl

prefLabel

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

@en

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

@nl

P1433

Q37164590-9F4A4514-CF12-4EA5-A97D-93C2F05E5925

P1476

Q37164590-5B754F1F-BADD-4FB6-B6D7-CBEA23ADEC52

P2093

Q37164590-36DF03E7-1A39-468F-8E93-E2C0F3F985DA

Q37164590-51F38963-04A2-4CB2-A3DA-5B84E257D26F

Q37164590-907B26D0-82F6-4659-B7B2-AFAECEC94009

Q37164590-A46D3F35-099D-4E27-9C62-F0DED4CC0D7F

Q37164590-E8C236FA-67D8-4BCB-8CFA-C959AC8E1654

Q37164590-EDF2620E-039E-410B-9B59-2373E56F2337

P2860

Q37164590-0439E328-C756-49C2-B5E6-CD6392404898

Q37164590-11A68073-3E3B-4398-A05E-D1AD6EB22B6E

Q37164590-12D63ADA-9E37-44E1-B904-21D5B30C73FA

Q37164590-21AC2FF9-932F-41F3-BA0B-444F4F49260C

Q37164590-2907F44B-3571-4A56-8E92-CB263B7A27BE

Q37164590-29CF2D0B-6751-461D-AD82-CB10B2A04C05

Q37164590-2E1F9F38-0E0F-48D3-B6B9-FA5C01273E28

Q37164590-2FAB75B5-D7B0-47BE-9984-F2E986AA40CB

Q37164590-354B5DE3-0698-40EE-89EE-6460ACFFD945

Q37164590-3B312810-670B-431B-A31E-0E8A4A26E881

P304

Q37164590-4C39B6EC-AFB2-4FED-B149-CCBD16C9B979

P31

Q37164590-A1571471-05CA-4955-BF8C-4352AC3E5CE5

P356

Q37164590-65562321-AEC7-4920-A1D1-FD81C3B132B5

P433

Q37164590-78B2BD5A-5F76-4220-831F-7DFF49B9C3A4

P478

Q37164590-71E3AA88-CFBA-47D2-92E4-D075E24CE8D6

P50

Q37164590-8F3600C3-8950-48EA-B834-CA5A5CAACDA4

P577

Q37164590-AC5B9973-E42E-4C22-95AF-D02945F4FB42

P698

Q37164590-D709718B-E878-4175-9351-CDB7100EAFC3

P921

Q37164590-B2752C86-E06F-4158-B2D2-4F8DE5458387

P932

Q37164590-CB230747-469D-4CE0-AD55-8A44E283F83F

P356

J.JTHO.2015.12.103

P1433

Journal of Thoracic Oncology

P1476

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

@en

P2093

Bruce E Johnson

http://www.w3.org/2001/XMLSchema#string

Christine A Lydon

http://www.w3.org/2001/XMLSchema#string

David M Jackman

http://www.w3.org/2001/XMLSchema#string

Jessica J Lin

http://www.w3.org/2001/XMLSchema#string

Stephanie Cardarella

http://www.w3.org/2001/XMLSchema#string

Suzanne E Dahlberg

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

P304

556-565

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JTHO.2015.12.103

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-12-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26724471

http://www.w3.org/2001/XMLSchema#string

P921

P932

4979601

http://www.w3.org/2001/XMLSchema#string